Cost-effectiveness analysis of three strategies of erlotinib treatment in non small-cell lung cancer: A prospective multicentric French study (ERMETIC)
I. Borget, J. Cadranel, A. Mauguen, E. Quoix, B. Coudert, J. Madeleine, E. Dansin, V. Westeel, A. Madroszyk, S. Friard, C. Daniel, F. Morin, J. P. Pignon, C. Chouaid (Villejuif, Paris, , Dijon, Caen, Lille, Besancon, Marseille, Saint-Cloud, France)
Source: Annual Congress 2010 - Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Oral Presentation
Number: 365
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Borget, J. Cadranel, A. Mauguen, E. Quoix, B. Coudert, J. Madeleine, E. Dansin, V. Westeel, A. Madroszyk, S. Friard, C. Daniel, F. Morin, J. P. Pignon, C. Chouaid (Villejuif, Paris, , Dijon, Caen, Lille, Besancon, Marseille, Saint-Cloud, France). Cost-effectiveness analysis of three strategies of erlotinib treatment in non small-cell lung cancer: A prospective multicentric French study (ERMETIC). Eur Respir J 2010; 36: Suppl. 54, 365
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: